Zalcman, G <br/><br/>
[New biological treatments for lung cancer].  [electronic resource] 

 -  Revue de pneumologie clinique  Feb 2007 
 - 20-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>0761-8417 
<br/><br/><label>Standard No.: </label>10.1016/s0761-8417(07)90085-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--administration & dosage<br/>Bevacizumab<br/>Biopsy<br/>Clinical Trials as Topic<br/>Clinical Trials, Phase II as Topic<br/>Clinical Trials, Phase III as Topic<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride<br/>Female<br/>Forecasting<br/>Gefitinib<br/>Humans<br/>Lung--pathology<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Mutation<br/>Patient Selection<br/>Polymerase Chain Reaction<br/>Prospective Studies<br/>Protein Kinase Inhibitors--administration & dosage<br/>Quinazolines--administration & dosage<br/>Receptor Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Survival Analysis<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors